Tysabri related Press Releases
BMRI DATA SHOWING TYSABRI PROMOTED REMYELINATION PRESENTED AT THE 61ST ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY
BMRI DATA SHOWING TYSABRI PROMOTED REMYELINATION PRESENTED AT THE 61ST ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY Additional data suggests improvement in TYSABRI patients across clinical and
... Read more...EU Panel Recommends Update For Elan, Biogen's Tysabri Label
EU Panel Recommends Update For Elan, Biogen's Tysabri Label ZURICH -(Dow Jones)- European Medicines Agency, an advisory body to the European drugs regulator, said Thursday it recommends an update of... Read more...
TYSABRI® DEMONSTRATES SUSTAINED IMPROVEMENT IN FUNCTIONAL OUTCOMES IN MULTIPLE SCLEROSIS PATIENTS ACCORDING TO NEW POST-HOC ANAL
TYSABRI® DEMONSTRATES SUSTAINED IMPROVEMENT IN FUNCTIONAL OUTCOMES IN MULTIPLE SCLEROSIS PATIENTS ACCORDING TO NEW POST-HOC ANALYSIS TYSABRI is the Only Marketed MS Treatment to Show Both... Read more...
First Multiple Myeloma Patient Treated
Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI® in Oncology First Multiple Myeloma Patient Treated CAMBRIDGE, Mass. & DUBLIN, Ireland--(BUSINESS WIRE)--Sept. 5, 2008--Elan... Read more...
FDA Updates the Information for Healthcare Professionals Sheet for Tysabri (natalizumab)
FDA Updates the Information for Healthcare Professionals Sheet for Tysabri (natalizumab) Information for Healthcare Professionals Natalizumab Injection for Intraveneous Use (marketed as Tysabri)... Read more...
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges




